SCHEMBL3924488

SCHEMBL3924488

COc1ccc(C=O)cc1OCCCCl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.71
ALDH1A1 P00352 13/20 0.66
TSHR P16473 1/20 0.66
MAPT P10636 10/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
LMNA P02545 4/20 0.65
NPSR1 Q6W5P4 2/20 0.65
HTT P42858 2/20 0.65
HPGD P15428 8/20 0.56
CYP2C9 P11712 3/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CYP2D6 P10635 1/20 0.56
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
HSP90AA1 P07900 1/20 0.53
AOX1 Q06278 1/20 0.51
TRIM24 O15164 1/20 0.51
ALDH5A1 P51649 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30462849 1.00 FDPS (0.71) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL458083 0.94 FDPS (0.81) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL30462864 0.94 FDPS (0.71) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL4409432 0.94 FDPS (0.71) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL30462879 0.94 FDPS (0.81) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL5974454 0.92 FDPS (0.77) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL5974612 0.90 FDPS (0.75) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL13590011 0.90 FDPS (0.75) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL7661907 0.90 FDPS (0.86) FDPSALDH1A1TSHRMAPTSMN1; SMN2
SCHEMBL28335185 0.88 FDPS (0.77) FDPSALDH1A1TSHRMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283936-A Substituted amino ether-containing 2, 2-dimethyl benzopyran derivative and salt or solvate thereof, preparation and application thereof, and composition 沈阳药科大学 2023-06-23 CN disclosed
US-20230115176-A1 Complement Modulators and Related Methods RA PHARMACEUTICALS, INC. 2023-04-13 US disclosed
EP-3947352-A1 COMPLEMENT MODULATORS AND RELATED METHODS RA Pharmaceuticals, Inc. (US) 2022-02-09 EP disclosed
WO-2020205501-A1 COMPLEMENT MODULATORS AND RELATED METHODS RA PHARMACEUTICALS, INC. (US) 2020-10-08 WO disclosed
US-8361996-B2 Imidazolyl substituted steroidal and indan-1-one derivatives COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2013-01-29 US disclosed
CN-101291950-B Novel series of imidazolyl substituted steroidal and indan-1-one derivatives COUNCIL SCIENT IND RES 2013-01-02 CN disclosed
EP-1934241-B1 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL SCIENT IND RES (IN) 2012-11-14 EP disclosed
EP-1698635-B1 BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF KISSEI PHARMACEUTICAL (JP) 2011-12-14 EP disclosed
US-7547680-B2 Benzimidazole derivatives and medical uses thereof KISSEI PHARMACEUTICALS, CO., LTD. (JP) 2009-06-16 US disclosed
US-20090137541-A1 Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2009-05-28 US disclosed
CN-101291950-A Novel series of imidazolyl substituted steroidal and indan-1-one derivatives COUNCIL SCIENT IND RES (IN) 2008-10-22 CN disclosed
EP-1934241-A2 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2008-06-25 EP disclosed
US-20080038242-A1 Benzimidazole derivatives and medical uses thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 US disclosed
WO-2007031833-A2 NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-03-22 WO disclosed
EP-1698635-A1 BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115176-A1 Complement Modulators and Related Methods C5, C9, C1QBP FDPS 646/4885ALDH1A1 4659/4885TSHR 3798/4885
US-20080038242-A1 Benzimidazole derivatives and medical uses thereof SLCO1B3, SLCO2A1, SLCO2B1 FDPS 1459/4885ALDH1A1 1096/4885TSHR 1254/4885
US-20090137541-A1 Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives NR5A1, NR3C2, CYP17A1 FDPS 715/4885ALDH1A1 1121/4885TSHR 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.